medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2022, Number 1

<< Back Next >>

Acta Med 2022; 20 (1)

Estetrol: a new paradigm in gynecological therapy?

Navarrete HT, Guerrero CFJ, Valdés AP, Vázquez ELA

Language: Spanish
References: 49
Page: 50-57
PDF size: 207.94 Kb.


ABSTRACT

Estetrol (E4) is a natural estrogen produced by the human fetus and passes into the maternal blood at relatively high levels during pregnancy. Over the past two decades, its pharmacodynamic and pharmacokinetic profiles, tolerability, and safety margin have been shown to be highly favorable. In this sense, E4 potentially represents a great advance in gynecological therapy such as contraception and the management of menopause. E4 also shows applicability in other therapeutic fields such as hormone-dependent cancers (breast and prostate), osteoporosis, neuroprotection, muscle pain, and wound healing. We present hereinafter the current evidence on this "new" hormonal therapy option whose inclusion in gynecological clinical practice seems imminent.


REFERENCES

  1. Diczfalusy E. Endocrine functions of the human fetoplacental unit. Fed Proc. 1964; 23: 791-798. Reimpreso en: Am J Obstet Gynecol. 2005; 193 (6): 2024; discussion 2025.

  2. Zucconi G, Lisboa BP, Simonitsch E, Roth L, Hagen AA, Diczfalusy E. Isolation of 15-alpha-hydroxy-oestriol from pregnancy urine and from the urine of newborn infants. Acta Endocrinol (Copenh). 1967; 56 (3): 413-423. doi: 10.1530/acta.0.0560413.

  3. Holinka CF, Diczfalusy E, Coelingh Bennink HJ. Estetrol: a unique steroid in human pregnancy. J Steroid Biochem Mol Biol. 2008; 110 (1-2): 138-143. doi: 10.1016/j.jsbmb.2008.03.027.

  4. Visser M, Holinka CF, Coelingh Bennink HJ. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008; 11 Suppl 1: 31-40. doi: 10.1080/13697130802056511.

  5. Kundu N, Carmody PJ, Didolkar SM, Petersen LP. Sequential determination of serum human placental lactogen, estriol, and estetrol for assessment of fetal morbidity. Obstet Gynecol. 1978; 52 (5): 513-520.

  6. Kunzig HJ, Rolleke M, Schmitz-Rockerath B, Dean PG. Value of estetrol determinations in the management of intrauterine growth retardation. Comparison with free estriol. J Perinat Med. 1981; 9 (6): 302-310. doi: 10.1515/jpme.1981.9.6.302.

  7. Tulchinsky D, Frigoletto FD Jr, Ryan KJ, Fishman J. Plasma estetrol as an index of fetal well-being. J Clin Endocrinol Metab. 1975; 40 (4): 560-567. doi: 10.1210/jcem-40-4-560.

  8. Sciarra JJ, Tagatz GE, Notation AD, Depp R. Estriol and estetrol in amniotic fluid. Am J Obstet Gynecol. 1974; 118 (5): 626-642. doi: 10.1016/s0002-9378(16)33738-3.

  9. Notation AD, Tagatz GE. Unconjugated estriol and 15alpha-hydroxyestriol in complicated pregnancies. Am J Obstet Gynecol. 1977; 128 (7): 747-756. doi: 10.1016/0002-9378(77)90715-3.

  10. Martucci C, Fishman J. Uterine estrogen receptor binding of catecholestrogens and of estetrol (1,3,5(10)-estratriene-3,15alpha,16alpha,17beta-tetrol). Steroids. 1976; 27 (3): 325-333. doi: 10.1016/0039-128x(76)90054-4.

  11. Tseng L, Gurpide E. Competition of estetrol and ethynylestradiol with estradiol for nuclear binding in human endometrium. J Steroid Biochem. 1976; 7 (10): 817-822. doi: 10.1016/0022-4731(76)90184-9.

  12. Jozan S, Kreitmann B, Bayard F. Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. Acta Endocrinol (Copenh). 1981; 98 (1): 73-80. doi: 10.1530/acta.0.0980073.

  13. Holinka CF, Gurpide E. In vivo effects of estetrol on the immature rat uterus. Biol Reprod. 1979; 20 (2): 242-246. doi: 10.1093/biolreprod/20.2.242.

  14. Holinka CF, Bressler RS, Zehr DR, Gurpide E. Comparison of effects of estetrol and tamoxifen with those of estriol and estradiol on the immature rat uterus. Biol Reprod. 1980; 22: 913-926. doi: 10.1095/biolreprod22.4.913.

  15. Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008; 11 Suppl 1: 47-58. doi: 10.1080/13697130802073425.

  16. Warmerdam EG, Visser M, Coelingh Bennink HJ, Groen M. A new route of synthesis of estetrol. Climacteric. 2008; 11 Suppl 1: 59-63. doi: 10.1080/13697130802054078.

  17. Visser M, Foidart JM, Coelingh Bennink HJT. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric. 2008; 11 (Suppl 1): 64-68. doi: 10.1080/13697130802050340.

  18. Coelingh Bennink HJT, Singer C, Simoncini T, Genazzani AR, Holinka CF, Kubista E. Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. Climacteric. 2008; 11 (Suppl 1): 29. doi: 10.1080/13697130802040325.

  19. Coelingh Bennink HJT, Heegaard AM, Visser M, Holinka CF, Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008; 11 (Suppl 1): 2-14. doi: 10.1080/13697130701798692.

  20. Hammond GL, Hogeveen KN, Visser M, Coelingh Bennink HJT. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric. 2008; 11 (Suppl 1): 41-46. doi: 10.1080/13697130701851814.

  21. Heegaard AM, Holinka CF, Kenemans P, Coelingh Bennink HJT. Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test. Climacteric. 2008; 11 (Suppl 1): 22-28. doi: 10.1080/13697130701842490.

  22. Holinka CF, Brincat M, Coelingh Bennink HJT. Preventive effect of oral estetrol in a menopausal hot flush model. Climacteric. 2008; 11 (Suppl 1): 15-21. doi: 10.1080/13697130701822807.

  23. Coelingh Bennink HJT, Skouby S, Bouchard P, Holinka CF. Ovulation inhibition by estetrol in an in vivo model. Contraception. 2008; 77: 186-190. doi: 10.1016/j.contraception.2007.11.014.

  24. Estetrol (E4), the first NEST™. [Access 16-02-2021] Available in: https://www.mithra.com/en/estetrol

  25. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart JM, Gemzell-Danielson K. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study. Menopause. 2017; 24: 677-685. doi: 10.1097/GME.0000000000000823.

  26. Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart JM, Gemzell-Danielson K. Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Climacteric. 2017; 20 (3): 285-289. doi: 10.1080/13697137.2017.1291608.

  27. Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017; 22 (4): 245-254. doi: 10.1080/13625187.2017.1372571.

  28. Fishman J. Fate of 15a-hydroxyestriol-3H in adult man. J Clin Endocrinol. 1970; 31: 436-438. doi: 10.1210/jcem-31-4-436.

  29. Fishman J, Schut H, Solomon S. Metabolism, production and excretion rates of 15a-hydroxyestriol in late pregnancy. J Clin Endocrinol Metab. 1972; 35: 339-344. doi: 10.1210/jcem-35-3-339.

  30. Duijkers IJM, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. Eur J Contracept Reprod Health Care. 2015; 20: 476-489. doi: 10.3109/13625187.2015.1074675.

  31. Apter D, Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart JM et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016; 94 (4): 366-373. doi: 10.1016/j.contraception.2016.04.015.

  32. Apter D, Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart JM et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017; 22 (4): 260-267. doi: 10.1080/13625187.2017.1336532.

  33. Mawet M, Maillard C, Klipping C, Zimmerman Y, Foidart JM, Coelingh Bennink HJ. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care. 2015; 20 (6): 463-475. doi: 10.3109/13625187.2015.1068934.

  34. Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021; 103 (4): 213-221. doi: 10.1016/j.contraception.2021.01.001.

  35. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018; 141 (3): 287-294. doi: 10.1002/ijgo.12455.

  36. Archer D, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015; 92 (5): 439-444. doi: 10.1016/j.contraception.2015.07.014.

  37. Medical eligibility criteria for contraceptive use. Progestogen-only contraceptives. Geneva: World Health Organization. 2015. p. 157.

  38. Kluft C, Zimmerman Y, Mawet M, Klipping C, Duijkers IJM, Neuteboom J et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception. 2017; 95 (2): 140-147. doi: 10.1016/j.contraception.2016.08.018.

  39. Douxfils J, Klipping C, Duijkers I, Kinet V, Mawet M, Maillard C et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020; 102 (6): 396-402. doi: 10.1016/j.contraception.2020.08.015.

  40. Coelingh Bennink HJT, Verhoevena C, Zimmerman Y, Vissera M, Foidart JM, Gemzell-Danielsson K. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas. 2016; 91: 93-100. doi: 10.1016/j.maturitas.2016.06.017.

  41. Gaspard U, Taziaux M, Mawet M, Jost M, Gordenne V, Coelingh Bennink HJT et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020; 27 (8): 848-857. doi: 10.1097/GME.0000000000001561.

  42. Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017; 97 (3): 1045-1087. doi: 10.1152/physrev.00024.2016.

  43. Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014; 6 (10): 1328-1346. doi: 10.15252/emmm.201404112.

  44. Gérard C, Mestdagt M, Tskitishvili E, Communal L, Gompel A, Silva E et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015; 6 (19): 17621-1736. doi: 10.18632/oncotarget.4184.

  45. Giretti MS, Montt Guevara MM, Cecchi E, Mannella P, Palla G, Spina S et al. Effects of estetrol on migration and invasion in T47-D breast cancer cells through the actin cytoskeleton. Front Endocrinol (Lausanne). 2014; 5: 80. doi: 10.3389/fendo.2014.00080.

  46. Visser M, Kloosterboer HJ, Bennink HJ. Estetrol prevents and suppresses mammary tumors induced by DMBA in a rat model. Horm Mol Biol Clin Investig. 2012; 9 (1): 95-103. doi: 10.1515/hmbci-2012-0015.

  47. Singer CF, Bennink HJ, Natter C, Steurer S, Rudas M, Moinfar F et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014; 35 (11): 2447-2451. doi: 10.1093/carcin/bgu144.

  48. Schmidt M, Lenhard H, Hoenig A, Zimmerman Y, Krijgh J, Jansen M et al. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol. 2021; 147 (6): 1833-1842. doi: 10.1007/s00432-020-03472-8.

  49. Mauras N, Torres-Santiago L, Santen R, Mericq V, Ross J, Colon-Otero G et al. Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome. Clin Endocrinol (Oxf). 2019; 90 (1): 155-161. doi: 10.1111/cen.13869.




2020     |     www.medigraphic.com